Subtype
Breast Adenocarcinoma
CI-CAN-00002035Explore in graph →
686 active trials9 approved drugs104 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002035Explore in graph →
Clinical trials
1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (278)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03243331 | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | completed | Phase 1 | 18 | Kathy MillerOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| PCA062 in pCAD-positive Tumors. |
| completed |
| Phase 1 |
| 47 |
| Novartis PharmaceuticalsINDUSTRY |
| 6 |
| Dec 19, 2020 |
| clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03544125 | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01983501 | A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer | completed | Phase 1 | 57 | Seagen Inc.INDUSTRY | 2 | Sep 21, 2020 | clinicaltrials |
| NCT02622074 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | completed | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 10, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT02348320 | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02038010 | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx | completed | Phase 1 | 17 | Northwestern UniversityOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT02061332 | DC Vaccine for Patients With Ductal Carcinoma In Situ(DCIS6) | completed | Phase 1 / Phase 2 | 58 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01355393 | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01783756 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | completed | Phase 1 / Phase 2 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)(CLARITY-01) | completed | Phase 1 / Phase 2 | 175 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01632332 | Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer | completed | Phase 1 | 22 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02060253 | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT01624441 | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 30, 2018 | clinicaltrials |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | completed | Phase 1 | 112 | Merrimack PharmaceuticalsINDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00707707 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 4 | Mar 6, 2018 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00998036 | Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | completed | Phase 1 | 9 | Columbia UniversityOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT02135159 | Patients With Brain Metastases From HER2-positive Breast Cancer(BIRTH) | completed | Phase 1 | 36 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT01104259 | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer | completed | Phase 1 | 50 | University of WashingtonOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00331552 | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT00791037 | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00637481 | A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Dec 29, 2016 | clinicaltrials |
| NCT01372644 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial | completed | Phase 1 | 15 | NYU Langone HealthOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00573495 | Multipeptide Vaccine for Advanced Breast Cancer | completed | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01281150 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00070252 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 4, 2015 | clinicaltrials |
| NCT01238952 | Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer | completed | Phase 1 | 4 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01245205 | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2014 | clinicaltrials |
| NCT01077453 | Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer | completed | Phase 1 | 112 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jan 7, 2021source: clinicaltrials